Surrozen (SRZN) Other Non Operating Income (2021 - 2026)
Surrozen (SRZN) posted quarterly Other Non Operating Income of -$41.1 million for Q1 2026, down 208.22% year-over-year from $38.0 million in Q1 2025, and up 31.02% quarter-over-quarter from -$59.6 million in Q4 2025.
Surrozen (SRZN) Other Non Operating Income (2021 - 2026) Analysis & Trends
Surrozen's Other Non Operating Income history runs 6 years deep, the most recent figure standing at -$41.1 million for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 208.22% year-over-year to -$41.1 million; the TTM figure through Mar 2026 stood at -$105.4 million (down 662.18% YoY), while the FY2025 annual figure was -$26.3 million, down 36.18% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$41.1 million, up from -$59.6 million in the prior quarter.
- The five-year high for Other Non Operating Income was $38.0 million in Q1 2025, with the low at -$59.6 million in Q4 2025.
- The 5-year median for Other Non Operating Income is $83000.0 (2023), against an average of -$4.6 million.
- The sharpest annual moves came in 2022 and 2024: Other Non Operating Income soared 92100.0% in 2022, then plunged 6667.55% in 2024.
- Surrozen's Other Non Operating Income stood at $920000.0 in 2022, then sank by 67.17% to $302000.0 in 2023, then slumped by 6667.55% to -$19.8 million in 2024, then plunged by 200.46% to -$59.6 million in 2025, then surged by 31.02% to -$41.1 million in 2026.
- Business Quant data shows SRZN's Other Non Operating Income at -$41.1 million in Q1 2026, -$59.6 million in Q4 2025, and -$20.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.36 Mn |
| Mar 31, 2026 | -41.11 Mn |
| Dec 31, 2025 | -59.59 Mn |
| Sep 30, 2025 | -20.92 Mn |
| Jun 30, 2025 | 16.22 Mn |
| Mar 31, 2025 | 37.99 Mn |
| Dec 31, 2024 | -19.83 Mn |
| Sep 30, 2024 | -3.10 Mn |
| Jun 30, 2024 | 3.70 Mn |
| Mar 31, 2024 | -85,000.00 |
| Dec 31, 2023 | 302,000.00 |
| Sep 30, 2023 | 83,000.00 |
| Jun 30, 2023 | 265,000.00 |
| Mar 31, 2023 | -252,000.00 |
| Dec 31, 2022 | 920,000.00 |
| Sep 30, 2022 | 50,000.00 |
| Jun 30, 2022 | 87,000.00 |
| Mar 31, 2022 | 6.50 Mn |
| Dec 31, 2021 | -1,000.00 |
| Sep 30, 2021 | -328,000.00 |